Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure 1 by providing human cardiomyocytes to support heart regeneration 2 . Studies of human embryonic-stemcell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment 3-7 . However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that cryopreservation and intramyocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models 7
Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure 1 by providing human cardiomyocytes to support heart regeneration 2 . Studies of human embryonic-stemcell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment [3] [4] [5] [6] [7] . However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that cryopreservation and intramyocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models 7 , nonfatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.
Human pluripotent stem cells have indisputable cardiomyocytegenerating abilities and have been extensively investigated for repair of the injured heart 3, 4, [6] [7] [8] [9] [10] . These stem cells are derived either from developing blastocytsts (human embryonic stem (ES) cells) or from reprogrammed somatic cells (induced pluripotent stem cells (iPSCs)) 11 . Although iPSCs have promising therapeutic potential 12 , a number of factors are likely to slow their regulatory approval 2 . Human ES-cell derivatives, on the other hand, are already being tested in humans for retinal diseases and spinal cord injury 13, 14 . These indications require small numbers of differentiated cells, ranging from 10 4 to 10 7 . By contrast, cardiac repair will require orders of magnitude more cells, because a billion cardiomyocytes are lost after a typical infarct 2 . At present it is unknown whether this large-scale production of hESC-CMs is feasible. Furthermore, it remains unclear whether the favourable cardiac repair findings in small-animal models will be reproduced in more clinically relevant large-animal models. As an important translational step towards creating a viable clinical therapy, we investigated the ability of exogenously delivered hESC-CMs to engraft and electrically couple to host myocardium in a non-human primate model of myocardial infarction. Notably, this model provides a heart size and rate more comparable to the human.
Extrapolating results from our previous studies in smaller mammals, where 10 6 cardiomyocytes were required in mice, 10 7 in rats and 10 8 in guinea pigs [6] [7] [8] 15 , we reasoned that sufficient engraftment in the larger non-human primate heart required delivery of 1 3 10 9 cells. Feasibility of this large-scale hESC-CM delivery requires cryopreservation of cells, which we validated in an established immunodeficient mouse model of myocardial infarction 15 . Similar to previous reports 16 , we found no adverse impact of cryopreservation on hESC-CM graft size (Extended Data Fig. 1 ). Therefore, delivery of cryopreserved hESC-CMs seems to be a sound strategy for large-scale transplantation in large animals or humans.
We previously used zinc-finger nuclease (ZFN)-mediated gene targeting to create hESC-CMs (H7 parental ES-cell line) stably expressing the genetically encoded fluorescent calcium indicator GCaMP3 from the AAVS1 locus 7 (Extended Data Fig. 2a ). These were used to prove exogenously delivered hESC-CMs could electrically couple to the host heart in a guinea pig model of myocardial infarction 7 . For the first two non-human primate experiments we used this same cell line. Routine karyotyping after two experiments revealed duplication of the long arm of chromosome 20 (Extended Data Fig. 3a ). Reanalysis of two previous karyotypes from this line revealed this subtle duplication to be present in cells delivered to both monkeys. As the effect of this abnormality on hESC-CM engraftment and function is unknown, we created another karyoptyically normal GCaMP3 human ES-cell line for comparison. The ZFN approach was again used to target the GCaMP3 construct to the AAVS1 locus (Extended Data Fig. 2a ) in Rockefeller University embryonic stem cell line 2 (RUES2) human ES cells. Southern blotting revealed correct targeting of the construct (Extended Data Fig. 2b ) and karyotyping was normal after expansion (Extended Data Fig. 3b ). For both of these GCaMP3 ES-cell lines we used our well-established monolayer protocol of directed differentiation (as described earlier) to produce a high yield of cardiomyoctes 8 . Flow cytometry was used to assess cardiomyocyte purity, and the hESC-CMs used in these studies were 73 6 12% positive for cardiac troponin T (cTnT; Extended Data Fig. 4 ). Spontaneous beating was observed in vitro for hESC-GCaMP3-CMs with robust fluorescence with each contractile cycle (Supplementary Videos 1 and 2).
Seven pigtail macaques (Macaca nemestrina) were used for the study without randomization (Table 1) . Myocardial infarction was created by ischaemia followed by reperfusion using a percutaneous balloon catheter 2 weeks before hESC-CM delivery, with immunosuppression starting 5 days before cell delivery (see Methods and Extended Data Fig. 5 ). hESC-CMs were delivered into the infarct region and surrounding border zones under direct surgical visualization using a method optimized to aid cell retention (Extended Data Fig. 6 ). All macaques underwent full necropsy after being euthanized. Consistent with our previous results [6] [7] [8] 15 , no macroscopic or microscopic evidence of teratoma or other tumour was detected, and human cells were not identified outside the heart. All macaques had patchy transmural myocardial infarctions. Infarct sizes in sham-treated hearts (at 14 and 28 days after engraftment) were 7.3 and 10.4% of the left ventricle (Table 1) , whereas infarcts in cell-treated hearts ranged from 3.7-9.5% of the left ventricle (mean of 5.2 6 1.5%; Table 1 ). All hESC-CM-treated monkeys showed extensive remuscularization of the infarct areas ( Fig. 1a -g and Extended Data Fig. 7 ). Graft size, calculated on the basis of green fluorescence protein (GFP) expression, ranged from 0.7-5.3% of the left ventricle (mean of 2.1 6 1.1%; Table 1 ), averaging 40% of the infarct volume. Greater than 98% of engrafted human cells expressed the sarcomeric protein a-actinin (Extended Data Fig. 8a ), indicating that almost all graft cells were cardiomyocytes. Furthermore, these hESC-CMs showed increased maturation from day 14 to day 84, as evidenced by increased myofibril alignment, sarcomere registration and cardiomyocyte diameter ( Fig. 2a -c and Extended Data Fig. 8b-f ). As these conclusions are drawn from small animal numbers per time point (n 5 1 each for day 14 and day 84, n 5 2 for day 28), maturation will require further validation. The cardiomyocyte diameter of day 84 grafts was 10.9 6 2 mm, approximately the size of normal adult monkey cardiomyocytes (10.1 mm) and approaching the 11-13 mm diameter seen in normal adult human hearts 17 . Additionally, a maturation gradient was apparent, with cardiomyocytes at the edge of grafts exhibiting greater maturation than those within the central core ( Fig. 2f-k ). There were frequent host-graft contacts ( Fig. 1g ) where nascent intercalated disks formed and expressed the adherens junction protein N-cadherin and the gap junction protein connexin 43. From day 14 to day 84 the expression of these junctional proteins increased substantially ( Fig. 2d , e, l-q). Few CD3 1 T lymphocytes or CD20 1 B lymphocytes were found within or around the hESC-CM grafts, suggesting that our immunosuppression successfully prevented graft rejection (Extended Data Fig. 9 ).
hESC-CM grafts were perfused by host vessels, as evidenced by anti-CD31 immunostaining without GFP co-expression ( Fig. 1h , i). Microcomputed tomography was used to image the three-dimensional structure of the coronary vasculature, which was correlated to aligned histological sections, permitting analysis of coronary anatomy within the graft, scar and remote myocardium ( Fig. 3a-d and Supplementary Video 3). Graft and scar regions were integrated into the threedimensional vascular network, revealing arteries and veins supplying the hESC-CM graft that were connected to the host system. This shows, to our knowledge for the first time, that large hESC-CM grafts are successfully perfused by host vasculature and are viable long term.
To investigate electromechanical coupling of hESC-CM grafts to the host, hearts from all macaques were subjected to ex vivo fluorescent imaging using a modified Langendorff perfusion system (Supplementary Video 4). Hearts were perfused with 2,3-butanedione monoxime (BDM, a myosin crossbridge inhibitor) to uncouple electrical cardiomyocyte excitation from mechanical contraction. This removed confounding motion artefacts and prevented indirect graft activation by passive stretching. Epicardial fluorescent calcium transients were seen in all hESC-CM-treated hearts, indicating electrical activation of the cardiomyocyte grafts ( Fig. 4a-d and Supplementary Videos 5, 6). Furthermore, 100% of the visible hESC-CM grafts in every monkey showed electromechanical coupling to the host heart (Table 1) . Graft-host coupling was evidenced by epicardial fluorescent transients that were synchronous with the host electrocardiogram (ECG) QRS complexes during 
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spontaneous depolarization ( Fig. 4e ). hESC-CM grafts retained 1:1 coupling to host myocardium during atrial pacing at rates of up to 240 beats per minute, the highest rate tested ( Fig. 4f-h) .
To explore the electrophysiological consequences of our hESC-CM grafts, we analysed ECGs obtained by telemetry from the time of infarction until death. Continuous ECG recordings were taken regularly and 24 h periods (midnight to midnight) were analysed. Control macaques with myocardial infarctions and sham (vehicle only) injections maintained normal sinus rhythm with heart rates of 100-130 beats per minute throughout the experiment (Fig. 5a ). No arrhythmias were noted in hESC-CM-treated monkeys during the period after myocardial infarction but before hESC-CM delivery ( Fig. 5e-h) . By contrast, all macaques that received hESC-CMs showed arrhythmias. These included premature ventricular contractions and runs of ventricular tachycardia (defined as wide QRS complex (.60 ms) with rate .180 beats min 21 ; Fig. 5c ). Frequent wide QRS complex rhythms with rates similar to baseline (accelerated idioventricular rhythm; Fig. 5b ) were also observed. Notably, all animals remained conscious and in no distress during all periods of arrhythmia.
To investigate left ventricular function, we performed transoesophageal echocardiography before myocardial infarction, before hESC-CM delivery and immediately before the end of the experiment (Extended Data Fig. 10b ). Multiple trans-oesophageal and deep transgastric views were analysed by cardiologists blinded to experimental details. We were unable to obtain images of sufficient quality for analysis from one control animal. The other control demonstrated a decline in ejection fraction after myocardial infarction that was unchanged after sham cell injection. The hearts receiving hESC-CMs showed variable responses, some exhibiting an increased ejection fraction after treatment and others showing no improvement. Owing to the small group sizes, no statistically significant effects were noted.
These experiments demonstrate that hESCs can be grown, differentiated into cardiomyocytes and cryopreserved at a scale sufficient to treat a large-animal model of myocardial infarction. With further refinements in manufacturing, the scale up to trials in human patients seems feasible. Large-animal models are important forerunners to human trials, because they impart real-world rigour to issues such as cell production, delivery and end-point analyses, while permitting mechanistic studies not possible in patients 18, 19 . We observed extensive remuscularization of the infarcts in all animals, with grafts averaging 40% of infarct mass. Importantly, all of the human cardiomyocytes showed complete electrical coupling to the primate heart and responded normally to pacing up to 240 beats per minute (the fastest rate attempted). 
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The coupling seen in this study was greater than that observed in our guinea pig model, where only 60% of recipient hearts had grafts that were synchronized with the host 7 . This enhanced coupling may have resulted from the use of an ischaemia-reperfusion model, which gives patchier infarcts with more peninsulas of viable host tissue than the guinea pig cryo-injury model. Our previous studies in mice 15 , rats 6, 8 and guinea pigs 7 gave no evidence of arrhythmias after hESC-CM engraftment, whereas here we consistently observed arrhythmias. There are several possible mechanisms for the observed arrhythmias, including re-entrant circuits or graft automaticity [20] [21] [22] . Further studies are required to distinguish between these possibilities. The most likely reasons why arrhythmias were observed in monkeys but not in smaller animals seem to be differences in heart size and rate. Regarding size, the larger hearts of adult macaques (37-52 g) compared with the hearts of mice (0.15 g), rats (1 g) and guinea pigs (3 g) allows for more hESC-CMs to be delivered, and the resultant grafts are approximately tenfold larger than the largest obtained in other species 7 . Ventricular depolarization over integrated but relatively Interrupted y-axis in e, f denotes reduced number of episodes but increased total duration of arrhythmias (VT or AIVR for more than 18 h per 24 h period). NSAIVR, non-sustained accelerated idioventricular rhythm.
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immature hESC-CM grafts may slow conduction of the overall wave front. Although not problematic over short distances in small grafts, over longer distances (in large grafts) this may favour formation of re-entrant loops. It is noteworthy that the animal (P5) with the largest hESC-CM graft size also had the highest frequency of arrhythmia. Another important factor is the species-specific heart rates (macaques 100-130 beats min 21 versus guinea pigs 230 beats min 21 , rats ,400 beats min 21 and mice ,600 beats min 21 ). Faster spontaneous rates will favour ventricular capture from native conduction pathways rather than graft automaticity or re-entrant loops, and this would probably prevent sustained ventricular arrhythmias. These factors are relevant to clinical translation given that the human heart is larger (300 g) with a slower basal rate (70 beats min 21 ) than that of macaques.
The principal limitations of this study are the small numbers of animals used and their relatively small infarct sizes. Both limitations stem from the high cost and value of the primate model. Consequently, we cannot determine with statistical certainty that the observed arrhythmias directly result from transplanted hESC-CMs. Larger studies will be required to assess this and the treatment effects on cardiac function. Importantly, infarct sizes in this study were smaller than the clinically severe infarcts that might benefit most from hESC-CM therapy. Larger infarcts, in human hearts, might manifest more arrhythmias. Because ventricular arrhythmias can be life threatening, they need to be understood mechanistically and managed en route to safe clinical translation. Nevertheless, the extent of remuscularization and electromechanical coupling seen here encourages further development of human cardiomyocyte transplantation as a clinical therapy for heart failure.
METHODS SUMMARY
Human ES cells were differentiated into cardiomyocytes by induction with activin A and BMP4, as previously reported 7, 8 . To enhance engraftment cardiomyocytes were subjected to heat shock followed by treatment with a pro-survival cocktail before cryopreservation. GCaMP3-positive human ES cells were generated by ZFNmediated targeting to the AAVS1 locus, following methods described previously 7 . Details of mouse and macaque procedures are provided in Methods. Microcomputed tomography was performed as previously described 23 with minor modifications. All procedures complied with the regulations of and were approved by the University of Washington Institutional Animal Care and Use Committee.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell preparation. Undifferentiated H7 (ref. 11) or RUES2 human ES cells 24 were expanded using mouse embryonic fibroblast-conditioned medium (MEF-CM) 25 supplemented with basic fibroblast growth factor (R&D Systems). The H7 line was obtained from the WiCell Research Institute and the RUES2 line from Rockefeller University. Both lines were regularly karyotyped and tested for mycoplasma. Human ES cells were then differentiated into cardiomyocytes using a previously reported directed differentiation protocol. Briefly, activin A (R&D Systems) and bone morphogenetic protein 4 (BMP4, R&D) are applied to defined, serum-free, monolayer culture conditions 8, 26 . hESC-CMs were collected and cryopreserved after 16-20 days of CM differentiation. One day before collection, cells were subjected to a pro-survival 'cocktail' (PSC) protocol, previously shown to enhance engraftment after transplantation 8 . Briefly, cultures were heat-shocked with a 30 min exposure to 43 uC medium, followed by RPMI-B27 medium supplemented with IGF1 (100 ng ml 21 , Peprotech) and cyclosporine A (0.2 mM, Sandimmune, Novartis). One day later, cultures were collected with 0.25% trypsin per 0.5 mM EDTA (Invitrogen) and cryopreserved as described previously 7 . Immediately before transplantation, cells were thawed at 37 uC, washed with RPMI, and suspended in 1.5 ml volume (per animal) of modified PSC consisting of 50% (v/v) growthfactor-reduced Matrigel, supplemented with BCL-xl BH4 (cell-permeant TAT peptide, 50 nM, Calbiochem), cyclosporine A (200 nM, Wako), IGF1 (100 ng ml 21 , Peprotech) and pinacidil (50 mM, Sigma). Generation of the GCaMP-reporter human ES-cell line. A transgene encoding for the constitutive expression of GCaMP3 was inserted into the AAVS1 locus in H7 and RUES2 human ES cells, using methods adapted from a previous study 27 (see Extended Data Fig. 2 ). In brief, the right and left arms of an AAVS1-specific ZFN were de novo synthesized (Genscript) and cloned into a single polycistronic plasmid in which the expression of each was driven by an independent human PGK promoter. A second polycistronic vector was generated in which (approximately 800 bp) homology arms flanking the AAVS1 ZFN cut site (pZDonor, Sigma Aldrich) surrounded a 5.1 kb insert with two elements: a cassette in which the CAG promoter drives expression of GCaMP3 (Addgene, plasmid #22692) and a second cassette encoding for PGK-driven expression of neomycin resistance. AAVS1 ZFN (5 mg) and AAVS1 CAG GCaMP3 targeting vector plasmids were co-electroporated (Lonza, Nucleofection system) into human ES cells cultured in MEF-CM supplemented with 10 mM Y-27632. Green fluorescent colonies were isolated and expanded and selected with 40-100 mg ml 21 G418 (Invitrogen) for 5-10 days. Southern blot analysis. Wild-type and transgenic GCaMP3-positive human EScell genomic DNA were digested with the restriction enzymes NdeI and NheI, run on 1% polyacrylamide gel and transferred to a membrane (BioRad Zeta Probe). The membrane was washed in 23 SSC and dried at 80 uC in a hybridization oven for 2 h, followed by 1 h of pre-hybridization in 50% formamide, 0.12 M NaH2PO4, 0.25 M NaCl, 7% SDS and 1 mM EDTA at 43 uC. A genomic probe was generated using the following primers: GGAGGTGGTGCGCTTCTTGG (forward), CGC ATCCCCTCCCAGAAAGAC (reverse), and neomycin cassette probe: ATGGGA TCGGCCATTGAACAAG (forward), GAAGAACTCGTCAAGAAGGCG (reverse). The probes were labelled with p32 dCTP (Amersham Megaprime DNA labelling system) and hybridized overnight in hybridization buffer at 43 uC. After 24 h, the membrane was washed for 20 min with 23 SSC/0.1% SDS followed by 20 min in 0.13 SSC/0.1% SDS. The membrane was then exposed to autoradiographic film for 3 days. Animal models. All procedures complied with and were approved by the University of Washington Animal Care and Use Committee. Mouse surgery. Male, SCID-BEIGE mice of 8 weeks age, (Taconic Farm) were anaesthetized with Avertin, intubated and ventilated before undergoing thoracotomy and ligation of the left anterior descending artery. Immediately after ligation 1 3 10 5 hESC-CMs (freshly isolated or cryopreserved, allocated in a nonrandomized and unblinded manner) in a volume of 5 ml was injected directly into the infarct region and surrounding border zones. Five days after myocardial infarction creation mice were euthanized and hearts collected for analysis for detection of human cell grafts by previously described methods 15 (see later and Extended Data Fig. 1 ). Non-human primate surgery. M. nemestrina (8.6-12.3 kg, Washington National Primate Center) of either sex were used for these experiments. Ages are specified in Table 1 . Macaques first underwent a 2-week period of acclimation and training to wear a mesh jacket to prevent removal of intravenous (i.v.) catheter. Five days before myocardial infarction, macaques were treated with amiodarone 100 mg daily with feed 5 days before myocardial infarction and continued for a further 10 days after myocardial infarction. For all major surgery macaques were anaesthetized with ketamine and propofol, intubated and ventilated using sevoflurane to maintain anaesthesia. Fentanyl and buprenorphine were administered to provide perioperative and postoperative pain relief. Before each major surgery trans-oesophageal echocardiography was performed using a Phillips HD-11XE ultrasound machine with an S7 2 MHz trans-oesophageal probe.
Before myocardial infarction creation, an i.v. lidocaine bolus 1 mg kg 21 and infusion 20 mg kg 21 min 21 was used to prevent ventricular arrhythmias. Heparin was delivered i.v. to maintain activated clotting times of 250-350 s to prevent thrombosis. Under fluoroscopic guidance a 5F coronary catheter was used to engage the left main coronary artery. A guide wire and angioplasty balloon was passed into the mid-left anterior descending artery and the balloon inflated for 90 min. Myocardial infarction was confirmed by ST segment elevation on ECG and by subsequent serum assays for cardiac troponin and creatine kinase. For telemetric monitor implantation a CTA-D70 (Data Sciences International) transmitter was placed subcutaneously over the abdomen with leads tunnelled subcutaneously in a modified lead II configuration. Immune suppression was achieved by methylprednisolone i.v. 500 mg on the day before hESC-CM delivery then maintenance doses of 0.1-1.5 mg kg 21 until monkeys were euthanized, cyclosporine to maintain serum trough levels of 200-250 mg l 21 from 5 days before hESC-CM delivery until macaques were euthanized and Abatacept (CTLA4 immunoglobulin) 12.5 mg kg 21 on the day before hESC-CM and every 2 weeks thereafter. To prevent opportunistic infections broad-spectrum antibiotics and anti-fungal agents were administered.
On day 14 after myocardial infarction, macaques were anaesthetized and underwent left thoracotomy. The heart was exposed and a pericardial cradle created. The infarct region was directly visualized and hESC-CMs were delivered intramyocardially into the infarct region and adjacent border zones via 15 injections each of 100 ml volume. Needle tips were placed within a preformed mattress suture, and three injections were delivered via the same epicardial puncture, changing the trajectory of the needle for each. Before withdrawal of the needle the mattress suture was closed around the needle tip to facilitate cell retention. For control macaques, an equal volume of PSC-RPMI vehicle was injected in the same manner as for hESC-CM delivery. hESC-CM-treated animals also received epicardial application of 1-3 tissue-engineering constructs where hESC-CMs were seeded in a collagen scaffold. (These tissue engineered constructs did not adhere to the epicardial surface and were not recovered at the end of the experiment.) Euthanasia was induced by i.v. injection of pentobarbital and phenytoin (Beuthanasia-D) followed by supersaturated KCl and Beuthanasia (CIII). Hearts were removed and perfused with University of Wisconsin cardioplegia solution before transportation on ice for calcium imaging experiments. Seven macaques were subjected to myocardial infarction. One was euthanized 2 days post-infarction (no treatment) because of lower limb ischaemia secondary to arterial thrombosis, and this was the only animal excluded from analysis. All others survived to the completion of the experiment. Two macaques (one cell-treated and one vehicle-only control) were euthanized at day 14, three macaques (two cell-treated and one vehicle-only control) were euthanized at day 28, and one cell-treated monkey was euthanized 84 days (3 months) after hESC-CM delivery. Control and cell-treatment groups were allocated in an unblinded and non-randomized manner. PCR detection of human ES-cell grafts. A high-throughput method of human cell detection was used as previously reported 15 . Briefly, hearts from mice engrafted with hESC-CMs were washed, snap frozen in liquid nitrogen and homogenized using a dis-membranator (Braun). Samples were resuspended in 200 ml of RNase/ DNase-free water supplemented with proteinase K and Chelex beads. Samples were centrifuged and a 2 ml sample of the DNA-containing supernatant removed for subsequent PCR using Alu-specific primers. Data were compared to standard curves generated with known human DNA quantities. Imaging of GCaMP3-expresssing grafts. Intravital imaging of hearts with GCaMP3-positive grafts was performed on days 14, 28 or 84 after hESC-CM transplantation using ex vivo preparation. For these experiments, the heart was mounted on a gravity-fed Langendorff apparatus and then perfused at 100 mm Hg with modified Tyrode solution at 37 uC. The epicardial GCaMP3 signal was then recorded before and after supplementation of the perfusate with 2,3-butanedione monoxime (BDM; 20 mM) 28, 29 . GCAMP3 signal was visualized using an epifluorescence stereomicroscope (Nikon, SMZ 1000) equipped with an EXFO X-Cite illumination source. GCaMP3 was excited at 450-490 nm and bandpass filtered (500-550 nm) before detection by an electron-multiplying, charge-coupled device camera (Andor iXon 860 EM-CCD) controlled by Andor Solis software. GCaMP3 image acquisition was typically at 80-140 frames per second (f.p.s.). Signals from the charge-coupled device (CCD) camera and the surface ECG were fed through a computer for digital storage and off-line analysis using Andor software and Labchart. Echocardiography. Images were acquired with an HD11-XE (Phillips) with S7 2 MHz trans-oesophageal probe. Trans-oesophageal four-chamber, two-chamber and short axis views were collected together with deep trans-gastric short-axis views. Functional analysis was performed using XCelera (Phillips) software by two independent cardiologists blinded to experimental conditions.
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